Sex affects immunity

Journal of Autoimmunity

Volumn 38, Issue 2-3, 2012, Pages

  Pennell, Leesa M ^a,b   Galligan, Carole L ^a,b   Fish, Eleanor N ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Autoimmunity; Estrogen; MS; RA; Sex hormones; SLE

Indexed keywords

ANDROGEN; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GAMMA INTERFERON; GESTAGEN; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; PROGESTERONE; PROLACTIN; SEX HORMONE; TESTOSTERONE;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL COUNT; GENETIC ASSOCIATION; HUMAN; HUMORAL IMMUNITY; IMMUNOTHERAPY; INNATE IMMUNITY; LEUKOCYTE; MENSTRUATION; MONOCYTE; MULTIPLE SCLEROSIS; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SEX DIFFERENCE; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TH1 CELL; TH2 CELL; X CHROMOSOME;

ANIMALS; AUTOIMMUNE DISEASES; DISEASE SUSCEPTIBILITY; FEMALE; GONADAL STEROID HORMONES; HUMANS; IMMUNITY; MALE; SEX FACTORS; X CHROMOSOME;

EID: 84858752881     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2011.11.013     Document Type: Review

References (163)

1. Klein S.L., Jedlicka A., Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis 2010, 10(5):338-349.
2. Bouman A., Heineman M.J., Faas M.M. Sex hormones and the immune response in humans. Hum Reprod Update 2005, 11(4):411-423.
3. Ackerman L.S. Sex hormones and the genesis of autoimmunity. Arch Dermatol 2006, 142(3):371-376.
4. Gleicher N., Barad D.H. Gender as risk factor for autoimmune diseases. J Autoimmun 2007, 28(1):1-6.
5. Rubtsov A.V., Rubtsova K., Kappler J.W., Marrack P. Genetic and hormonal factors in female-biased autoimmunity. Autoimmun Rev 2010, 9(7):494-498.
6. Dao H., Kazin R.A. Gender differences in skin: a review of the literature. Gend Med 2007, 4(4):308-328.
7. Fish E.N. The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol 2008, 8(9):737-744.
8. Ghazeeri G., Abdullah L., Abbas O. Immunological differences in women compared with men: overview and contributing factors. Am J Reprod Immunol 2011, 66(3):163-169.
9. Lockshin M.D. Nonhormonal explanations for sex discrepancy in human illness. Ann N Y Acad Sci 2010, 1193:22-24.
10. Uz E., Loubiere L.S., Gadi V.K., Ozbalkan Z., Stewart J., Nelson J.L., et al. Skewed X-chromosome inactivation in scleroderma. Clin Rev Allergy Immunol 2008, 34(3):352-355.
11. Broen J.C., Wolvers-Tettero I.L., Geurts-van Bon L., Vonk M.C., Coenen M.J., Lafyatis R., et al. Skewed X chromosomal inactivation impacts T regulatory cell function in systemic sclerosis. Ann Rheum Dis 2010, 69(12):2213-2216.
12. Dillon S., Aggarwal R., Harding J.W., Li L.J., Weissman M.H., Li S., et al. Klinefelter's syndrome (47, XXY) among men with systemic lupus erythematosus. Acta Paediatr 2011, 100(6):819-823.
13. Sawalha A.H., Webb R., Han S., Kelly J.A., Kaufman K.M., Kimberly R.P., et al. Common variants within MECP2 confer risk of systemic lupus erythematosus. PLoS One 2008, 3(3):e1727.
14. Chagnon P., Schneider R., Hebert J., Fortin P.R., Provost S., Belisle C., et al. Identification and characterization of an Xp22.33;Yp11.2 translocation causing a triplication of several genes of the pseudoautosomal region 1 in an XX male patient with severe systemic lupus erythematosus. Arthritis Rheum 2006, 54(4):1270-1278.
15. Carrel L., Willard H.F. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature 2005, 434(7031):400-404.
16. Pinheiro I., Dejager L., Libert C. X-chromosome-located microRNAs in immunity: might they explain male/female differences?: the X chromosome-genomic context may affect X-located miRNAs and downstream signaling, thereby contributing to the enhanced immune response of females. Bioessays 2011, 33(11):791-802.
17. Dai R., Ahmed S.A. MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Transl Res 2011, 157(4):163-179.
18. Lindsay M.A. microRNAs and the immune response. Trends Immunol 2008, 29(7):343-351.
19. Cunningham M., Gilkeson G. Estrogen receptors in immunity and autoimmunity. Clin Rev Allergy Immunol 2011, 40(1):66-73.
20. Heldring N., Pike A., Andersson S., Matthews J., Cheng G., Hartman J., et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007, 87(3):905-931.
21. Rider V., Li X., Peterson G., Dawson J., Kimler B.F., Abdou N.I. Differential expression of estrogen receptors in women with systemic lupus erythematosus. J Rheumatol 2006, 33(6):1093-1101.
22. Ishizuka M., Hatori M., Suzuki T., Miki Y., Darnel A.D., Tazawa C., et al. Sex steroid receptors in rheumatoid arthritis. Clin Sci (Lond) 2004, 106(3):293-300.
23. Benten W.P., Lieberherr M., Giese G., Wunderlich F. Estradiol binding to cell surface raises cytosolic free calcium in T cells. FEBS Lett 1998, 422(3):349-353.
24. Hill L., Jeganathan V., Chinnasamy P., Grimaldi C., Diamond B. Differential roles of estrogen receptors alpha and beta in control of B-cell maturation and selection. Mol Med 2011, 17(3-4):211-220.
25. Grimaldi C.M., Michael D.J., Diamond B. Cutting edge: expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. J Immunol 2001, 167(4):1886-1890.
26. Grimaldi C.M., Cleary J., Dagtas A.S., Moussai D., Diamond B. Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest 2002, 109(12):1625-1633.
27. Venkatesh J., Peeva E., Xu X., Diamond B. Cutting Edge: hormonal milieu, not antigenic specificity, determines the mature phenotype of autoreactive B cells. J Immunol 2006, 176(6):3311-3314.
28. Verthelyi D. Sex hormones as immunomodulators in health and disease. Int Immunopharmacol 2001, 1(6):983-993.
29. Pauklin S., Sernandez I.V., Bachmann G., Ramiro A.R., Petersen-Mahrt S.K. Estrogen directly activates AID transcription and function. J Exp Med 2009, 206(1):99-111.
30. Goodnow C.C. Multistep pathogenesis of autoimmune disease. Cell 2007, 130(1):25-35.
31. Hsu H.C., Wu Y., Yang P., Wu Q., Job G., Chen J., et al. Overexpression of activation-induced cytidine deaminase in B cells is associated with production of highly pathogenic autoantibodies. J Immunol 2007, 178(8):5357-5365.
32. Grimaldi C.M., Hill L., Xu X., Peeva E., Diamond B. Hormonal modulation of B cell development and repertoire selection. Mol Immunol 2005, 42(7):811-820.
33. Shames R.S. Gender differences in the development and function of the immune system. J Adolesc Health 2002, 30(4 Suppl):59-70.
34. Tanriverdi F., Silveira L.F., MacColl G.S., Bouloux P.M. The hypothalamic-pituitary-gonadal axis: immune function and autoimmunity. J Endocrinol 2003, 176(3):293-304.
35. Seli E., Kayisli U.A., Selam B., Seli M., Arici A. Estradiol suppresses vascular monocyte chemotactic protein-1 expression during early atherogenesis. Am J Obstet Gynecol 2002, 187(6):1544-1549.
36. Orbach H., Shoenfeld Y. Hyperprolactinemia and autoimmune diseases. Autoimmun Rev 2007, 6(8):537-542.
37. Olsen N.J., Kovacs W.J. Gonadal steroids and immunity. Endocr Rev 1996, 17(4):369-384.
38. Zandman-Goddard G., Peeva E., Shoenfeld Y. Gender and autoimmunity. Autoimmun Rev 2007, 6(6):366-372.
39. Sader M.A., McGrath K.C., Hill M.D., Bradstock K.F., Jimenez M., Handelsman D.J., et al. Androgen receptor gene expression in leucocytes is hormonally regulated: implications for gender differences in disease pathogenesis. Clin Endocrinol (Oxf) 2005, 62(1):56-63.
40. Szekeres-Bartho J., Barakonyi A., Par G., Polgar B., Palkovics T., Szereday L. Progesterone as an immunomodulatory molecule. Int Immunopharmacol 2001, 1(6):1037-1048.
41. Saha S., Tieng A., Pepeljugoski K.P., Zandamn-Goddard G., Peeva E. Prolactin, systemic lupus erythematosus, and autoreactive B cells: lessons learnt from murine models. Clin Rev Allergy Immunol 2011, 40(1):8-15.
42. Altuwaijri S., Chuang K.H., Lai K.P., Lai J.J., Lin H.Y., Young F.M., et al. Susceptibility to autoimmunity and B cell resistance to apoptosis in mice lacking androgen receptor in B cells. Mol Endocrinol 2009, 23(4):444-453.
43. Benten W.P., Lieberherr M., Giese G., Wrehlke C., Stamm O., Sekeris C.E., et al. Functional testosterone receptors in plasma membranes of T cells. FASEB J 1999, 13(1):123-133.
44. McMurray R.W. Estrogen, prolactin, and autoimmunity: actions and interactions. Int Immunopharmacol 2001, 1(6):995-1008.
45. Lahita R.G. Sex hormones and systemic lupus erythematosus. Rheum Dis Clin North Am 2000, 26(4):951-968.
46. Chernyshov V.P., Vodianyk M.O., Hrekova S.P. Effect of female steroid hormones on expression of adhesion molecules by peripheral blood leukocytes. Fiziol Zh 2002, 48(6):46-53. [abstract].
47. England J.M., Bain B.J. Total and differential leucocyte count. Br J Haematol 1976, 33(1):1-7.
48. Steffl M., Telgen L., Schweiger M., Amselgruber W.M. Estrous cycle-dependent activity of neutrophils in the porcine endometrium: possible involvement of heat shock protein 27 and lactoferrin. Anim Reprod Sci 2010, 121(1-2):159-166.
49. Jiemtaweeboon S., Shirasuna K., Nitta A., Kobayashi A., Schuberth H.J., Shimizu T., et al. Evidence that polymorphonuclear neutrophils infiltrate into the developing corpus luteum and promote angiogenesis with interleukin-8 in the cow. Reprod Biol Endocrinol 2011, 9:79-89.
50. Molloy E.J., O'Neill A.J., Grantham J.J., Sheridan-Pereira M., Fitzpatrick J.M., Webb D.W., et al. Sex-specific alterations in neutrophil apoptosis: the role of estradiol and progesterone. Blood 2003, 102(7):2653-2659.
51. Northern A.L., Rutter S.M., Peterson C.M. Cyclic changes in the concentrations of peripheral blood immune cells during the normal menstrual cycle. Proc Soc Exp Biol Med 1994, 207(1):81-88.
52. Scotland R.S., Stables M.J., Madalli S., Watson P., Gilroy D.W. Sex-differences in resident immune cell phenotype underlies more efficient acute inflammatory responses in female mice. Blood 2011, E pub ahead of print. 10.1182/blood-2011-03-340281.
53. Bouman A., Schipper M., Heineman M.J., Faas M.M. Gender difference in the non-specific and specific immune response in humans. Am J Reprod Immunol 2004, 52(1):19-26.
54. Yovel G., Shakhar K., Ben-Eliyahu S. The effects of sex, menstrual cycle, and oral contraceptives on the number and activity of natural killer cells. Gynecol Oncol 2001, 81(2):254-262.
55. Amadori A., Zamarchi R., De Silvestro G., Forza G., Cavatton G., Danieli G.A., et al. Genetic control of the CD4/CD8 T-cell ratio in humans. Nat Med 1995, 1(12):1279-1283.
56. Xia H.J., Zhang G.H., Wang R.R., Zheng Y.T. The influence of age and sex on the cell counts of peripheral blood leukocyte subpopulations in Chinese rhesus macaques. Cell Mol Immunol 2009, 6(6):433-440.
57. Cihakova D., Talor M.V., Barin J.G., Baldeviano G.C., Fairweather D., Rose N.R., et al. Sex differences in a murine model of Sjogren's syndrome. Ann N Y Acad Sci 2009, 1173:378-383.
58. Pernis A.B. Estrogen and CD4 + T cells. Curr Opin Rheumatol 2007, 19(5):414-420.
59. Kawana K., Kawana Y., Schust D.J. Female steroid hormones use signal transducers and activators of transcription protein-mediated pathways to modulate the expression of T-bet in epithelial cells: a mechanism for local immune regulation in the human reproductive tract. Mol Endocrinol 2005, 19(8):2047-2059.
60. Karpuzoglu E., Zouali M. The multi-faceted influences of estrogen on lymphocytes: toward novel immuno-interventions strategies for autoimmunity management. Clin Rev Allergy Immunol 2011, 40(1):16-26.
61. Wang C., Dehghani B., Li Y., Kaler L.J., Vandenbark A.A., Offner H. Oestrogen modulates experimental autoimmune encephalomyelitis and interleukin-17 production via programmed death 1. Immunology 2009, 126(3):329-335.
62. Subramanian S., Yates M., Vandenbark A.A., Offner H. Oestrogen-mediated protection of experimental autoimmune encephalomyelitis in the absence of Foxp3+ regulatory T cells implicates compensatory pathways including regulatory B cells. Immunology 2011, 132(3):340-347.
63. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000, 192(7):1027-1034.
64. Khan D., Dai R., Karpuzoglu E., Ahmed S.A. Estrogen increases, whereas IL-27 and IFN-γ decrease, splenocyte IL-17 production in WT mice. Eur J Immunol 2010, 40(9):2549-2556.
65. Lee J.H., Ulrich B., Cho J., Park J., Kim C.H. Progesterone promotes differentiation of human cord blood fetal T cells into T regulatory cells but suppresses their differentiation into Th17 cells. J Immunol 2011, 187(4):1778-1787.
66. Polanczyk M.J., Carson B.D., Subramanian S., Afentoulis M., Vandenbark A.A., Ziegler S.F., et al. Cutting edge: estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J Immunol 2004, 173(4):2227-2230.
67. Arruvito L., Sanz M., Banham A.H., Fainboim L. Expansion of CD4+CD25+and FOXP3+ regulatory T cells during the follicular phase of the menstrual cycle: implications for human reproduction. J Immunol 2007, 178(4):2572-2578.
68. Thuere C., Zenclussen M.L., Schumacher A., Langwisch S., Schulte-Wrede U., Teles A., et al. Kinetics of regulatory T cells during murine pregnancy. Am J Reprod Immunol 2007, 58(6):514-523.
69. Mjosberg J., Berg G., Jenmalm M.C., Ernerudh J. FOXP3+ regulatory T cells and T helper 1, T helper 2, and T helper 17 cells in human early pregnancy decidua. Biol Reprod 2010, 82(4):698-705.
70. Varghese S., Crocker I., Bruce I.N., Tower C. Systemic lupus erythematosus, regulatory T cells and pregnancy. Expert Rev Clin Immunol 2011, 7(5):635-648.
71. Lawson C.A., Brown A.K., Bejarano V., Douglas S.H., Burgoyne C.H., Greenstein A.S., et al. Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood. Rheumatology 2006, 45(10):1210-1217.
72. Viglietta V., Baecher-Allan C., Weiner H.L., Hafler D.A. Loss of functional suppression by CD4+CD25 + Regulatory T cells in patients with multiple sclerosis. J Exp Med 2004, 199(7):971-979.
73. Valor L., Teijeiro R., Aristimuno C., Faure F., Alonso B., de Andres C., et al. Estradiol-dependent perforin expression by human regulatory T-cells. Eur J Clin Invest 2011, 41(4):357-364.
74. Luo C.Y., Wang L., Sun C., Li D.J. Estrogen enhances the functions of CD4(+)CD25(+)Foxp3(+) regulatory T cells that suppress osteoclast differentiation and bone resorption in vitro. Cell Mol Immunol 2011, 8(1):50-58.
75. Cohen-Solal J.F., Jeganathan V., Grimaldi C.M., Peeva E., Diamond B. Sex hormones and SLE: influencing the fate of autoreactive B cells. Curr Top Microbiol Immunol 2006, 305:67-88.
76. Fillatreau S., Gray D., Anderton S.M. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol 2008, 8(5):391-397.
77. Li X., Braun J., Wei B. Regulatory B cells in autoimmune diseases and mucosal immune homeostasis. Autoimmunity 2011, 44(1):58-68.
78. Crispin J.C., Liossis S.N., Kis-Toth K., Lieberman L.A., Kyttaris V.C., Juang Y.T., et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 2010, 16(2):47-57.
79. Gayed M., Gordon C. Pregnancy and rheumatic diseases. Rheumatology (Oxford) 2007, 46(11):1634-1640.
80. Vukusic S., Hutchinson M., Hours M., Moreau T., Cortinovis-Tourniaire P., Adeleine P., et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004, 127(Pt 6):1353-1360.
81. Oliver J.E., Silman A.J. Why are women predisposed to autoimmune rheumatic diseases?. Arthritis Res Ther 2009, 11(5):252.
82. Mitchell K., Kaul M., Clowse M.E. The management of rheumatic diseases in pregnancy. Scand J Rheumatol 2010, 39(2):99-108.
83. Sawalha A.H., Kovats S. Dehydroepiandrosterone in systemic lupus erythematosus. Curr Rheumatol Rep 2008, 10(4):286-291.
84. Cutolo M. Estrogen metabolites: increasing evidence for their role in rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 2004, 31(3):419-421.
85. Colasanti T., Maselli A., Conti F., Sanchez M., Alessandri C., Barbati C., et al. Autoantibodies to estrogen receptor alpha interfere with T lymphocyte homeostasis and are associated with disease activity in systemic lupus erythematosus. Arthritis Rheum 2011, E pub ahead of print. 10.1002/art.33400.
86. Hooks J.J., Moutsopoulos H.M., Geis S.A., Stahl N.I., Decker J.L., Notkins A.L. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979, 301(1):5-8.
87. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003, 100(5):2610-2615.
88. Kirou K.A., Lee C., George S., Louca K., Papagiannis I.G., Peterson M.G., et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004, 50(12):3958-3967.
89. Bauer J.W., Baechler E.C., Petri M., Batliwalla F.M., Crawford D., Ortmann W.A., et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006, 3(12):e491.
90. Ronnblom L.E., Alm G.V., Oberg K.E. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 1990, 227(3):207-210.
91. Niewold T.B., Swedler W.I. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 2005, 24(2):178-181.
92. Panchanathan R., Shen H., Zhang X., Ho S.M., Choubey D. Mutually positive regulatory feedback loop between interferons and estrogen receptor-alpha in mice: implications for sex bias in autoimmunity. PLoS One 2010, 5(5):e10868.
93. Choubey D., Panchanathan R., Duan X., Liu H. Emerging roles for the interferon-inducible p200-family proteins in sex bias in systemic lupus erythematosus. J Interferon Cytokine Res 2010, 30(6):371-380.
94. Rider V., Jones S., Evans M., Bassiri H., Afsar Z., Abdou N.I. Estrogen increases CD40 ligand expression in T cells from women with systemic lupus erythematosus. J Rheumatol 2001, 28(12):2644-2649.
95. Huber J.P., Ramos H.J., Gill M.A., Farrar J.D. Cutting edge: type I IFN reverses human Th2 commitment and stability by suppressing GATA3. J Immunol 2010, 185(2):813-817.
96. Costenbader K.H., Feskanich D., Stampfer M.J., Karlson E.W. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum 2007, 56(4):1251-1262.
97. Abdou N.I., Rider V., Greenwell C., Li X., Kimler B.F. Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial. J Rheumatol 2008, 35(5):797.
98. Yildirim-Toruner C., Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol 2011, 127(2):303-312.
99. Takahashi T., Tanaka M., Brannan C.I., Jenkins N.A., Copeland N.G., Suda T., et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994, 76(6):969-976.
100. Watanabe T., Sakai Y., Miyawaki S., Shimizu A., Koiwai O., Ohno K. A molecular genetic linkage map of mouse chromosome 19, including the lpr, Ly-44, and Tdt genes. Biochem Genet 1991, 29(7-8):325-335.
101. Gaipl U.S., Voll R.E., Sheriff A., Franz S., Kalden J.R., Herrmann M. Impaired clearance of dying cells in systemic lupus erythematosus. Autoimmun Rev 2005, 4(4):189-194.
102. Ren Y., Tang J., Mok M.Y., Chan A.W., Wu A., Lau C.S. Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum 2003, 48(10):2888-2897.
103. Cairns A.P., Crockard A.D., McConnell J.R., Courtney P.A., Bell A.L. Reduced expression of CD44 on monocytes and neutrophils in systemic lupus erythematosus: relations with apoptotic neutrophils and disease activity. Ann Rheum Dis 2001, 60(10):950-955.
104. Herrmann M., Voll R.E., Zoller O.M., Hagenhofer M., Ponner B.B., Kalden J.R. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998, 41(7):1241-1250.
105. Sule S., Rosen A., Petri M., Akhter E., Andrade F. Abnormal production of pro- and anti-inflammatory cytokines by lupus monocytes in response to apoptotic cells. PLoS One 2011, 6(3):e17495.
106. Mor G., Sapi E., Abrahams V.M., Rutherford T., Song J., Hao X.Y., et al. Interaction of the estrogen receptors with the fas ligand promoter in human monocytes. J Immunol 2003, 170(1):114-122.
107. Kim W.U., Min S.Y., Hwang S.H., Yoo S.A., Kim K.J., Cho C.S. Effect of oestrogen on T cell apoptosis in patients with systemic lupus erythematosus. Clin Exp Immunol 2010, 161(3):453-458.
108. Kanda N., Tsuchida T., Tamaki K. Estrogen enhancement of anti-double-stranded DNA antibody and immunoglobulin G production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum 1999, 42(2):328-337.
109. Runmarker B., Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993, 116(1):117-134.
110. Weinshenker B.G., Rice G.P.A., Noseworthy J.H., Carriere W., Baskerville J., Ebers G.C. The natural history of multiple sclerosis: a geographically based study. Brain 1991, 114(2):1045-1056.
111. Debouverie M., Pittion-Vouyovitch S., Louis S., Guillemin F. Natural history of multiple sclerosis in a population-based cohort. Eur J Neurol 2008, 15(9):916-921. for the, L.G.
112. Greer J.M., McCombe P.A. Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms. J Neuroimmunol 2011, 234(1-2):7-18.
113. Greer J.M., Csurhes P.A., Pender M.P., McCombe P.A. Effect of gender on T-cell proliferative responses to myelin proteolipid protein antigens in patients with multiple sclerosis and controls. J Autoimmun 2004, 22(4):345-352.
114. Moldovan I.R., Cotleur A.C., Zamor N., Butler R.S., Pelfrey C.M. Multiple sclerosis patients show sexual dimorphism in cytokine responses to myelin antigens. J Neuroimmunol 2008, 193(1-2):161-169.
115. Achiron A., Gurevich M. Gender effects in relapsing-remitting multiple sclerosis: correlation between clinical variables and gene expression molecular pathways. J Neurol Sci 2009, 286(1-2):47-53.
116. Hensiek A.E., Sawcer S.J., Feakes R., Deans J., Mander A., Akesson E., et al. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry 2002, 72(2):184-187.
117. Mattila K.M., Luomala M., Lehtimäki T., Laippala P., Koivula T., Elovaara I. Interaction between ESR1 and HLA-DR2 may contribute to the development of MS in women. Neurology 2001, 56(9):1246-1247.
118. Sicotte N.L., Liva S.M., Klutch R., Pfeiffer P., Bouvier S., Odesa S., et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 2002, 52(4):421-428.
119. Gold S.M., Sasidhar M.V., Morales L.B., Du S., Sicotte N.L., Tiwari-Woodruff S.K., et al. Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through estrogen receptor alpha (ERalpha). Lab Invest 2009, 89(10):1076-1083.
120. Sicotte N.L., Giesser B.S., Tandon V., Klutch R., Steiner B., Drain A.E., et al. Testosterone treatment in multiple sclerosis: a pilot study. Arch Neurol 2007, 64(5):683-688.
121. Gold S.M., Chalifoux S., Giesser B.S., Voskuhl R.R. Immune modulation and increased neurotrophic factor production in multiple sclerosis patients treated with testosterone. J Neuroinflammation 2008, 5:32-40.
122. Confavreux C., Hutchinson M., Hours M.M., Cortinovis-Tourniaire P., Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. pregnancy in multiple sclerosis group. N Engl J Med 1998, 339(5):285-291.
123. Neuteboom R.F., Verbraak E., Voerman J.S., van Meurs M., Steegers E.A., de Groot C.J., et al. First trimester interleukin 8 levels are associated with postpartum relapse in multiple sclerosis. Mult Scler 2009, 15(11):1356-1358.
124. Achiron A., Kishner I., Dolev M., Stern Y., Dulitzky M., Schiff E., et al. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol 2004, 251(9):1133-1137.
125. Vukusic S., Ionescu I., El-Etr M., Schumacher M., Baulieu E.E., Cornu C., et al. The Prevention of post-partum relapses with progestin and estradiol in multiple sclerosis (POPART'MUS) trial: Rationale, objectives and state of advancement. J Neurol Sci 2009, 286(1-2):114-118.
126. Trojano M., Pellegrini F., Paolicelli D., Fuiani A., Zimatore G.B., Tortorella C., et al. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment. J Neurol Sci 2009, 286(1-2):109-113.
127. Li D.K., Zhao G.J., Paty D.W. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 2001, 56(11):1505-1513.
128. Wolinsky J.S., Shochat T., Weiss S., Ladkani D. Glatiramer acetate treatment in PPMS: why males appear to respond favorably. J Neurol Sci 2009, 286(1-2):92-98.
129. Papenfuss T.L., Powell N.D., McClain M.A., Bedarf A., Singh A., Gienapp I.E., et al. Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity. J Immunol 2011, 186(6):3346-3355.
130. Gabriel S.E. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001, 27(2):269-281.
131. Turesson C., O'Fallon W.M., Crowson C.S., Gabriel S.E., Matteson E.L. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002, 29(1):62-67.
132. Gabriel S.E., Crowson C.S., Kremers H.M., Doran M.F., Turesson C., O'Fallon W.M., et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003, 48(1):54-58.
133. Myasoedova E., Crowson C.S., Kremers H.M., Therneau T.M., Gabriel S.E. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum 2010, 62(6):1576-1582.
134. Sokka T., Toloza S., Cutolo M., Kautiainen H., Makinen H., Gogus F., et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther 2009, 11(1):R7.
135. Iikuni N., Sato E., Hoshi M., Inoue E., Taniguchi A., Hara M., et al. The influence of sex on patients with rheumatoid arthritis in a large observational cohort. J Rheumatol 2009, 36(3):508-511.
136. Walker S.E. Estrogen and autoimmune disease. Clin Rev Allergy Immunol 2011, 40(1):60-65.
137. Islander U., Jochems C., Lagerquist M.K., Forsblad-d'Elia H., Carlsten H. Estrogens in rheumatoid arthritis; the immune system and bone. Mol Cell Endocrinol 2011, 335(1):14-29.
138. Goemaere S., Ackerman C., Goethals K., De Keyser F., Van der Straeten C., Verbruggen G., et al. Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition. J Rheumatol 1990, 17(12):1620-1622.
139. Dziedziejko V., Kurzawski M., Safranow K., Chlubek D., Pawlik A. The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide. Pharmacogenomics 2011, 12(1):41-47.
140. Sato H., Ito A., Gonzalez-Canga A., Okuzawa H., Ugai K., Suzuki M., et al. Association of Rsa polymorphism of the estrogen receptor-beta gene with rheumatoid arthritis. Rheumatol Int 2011, E pub ahead of print. 10.1007/s00296-011-1947-2.
141. Holmdahl R., Klareskog L., Rubin K., Bjork J., Smedegard G., Jonsson R., et al. Role of T lymphocytes in murine collagen induced arthritis. Agents Actions 1986, 19(5-6):295-305.
142. Jansson L., Holmdahl R. Oestrogen induced suppression of collagen arthritis. IV: progesterone alone does not affect the course of arthritis but enhances the oestrogen-mediated therapeutic effect. J Reprod Immunol 1989, 15(2):141-150.
143. Jochems C., Islander U., Erlandsson M., Engdahl C., Lagerquist M., Gjertsson I., et al. Role of endogenous and exogenous female sex hormones in arthritis and osteoporosis development in B10.Q-ncf1*/* mice with collagen-induced chronic arthritis. BMC Musculoskelet Disord 2010, 11:284-292.
144. Walitt B., Pettinger M., Weinstein A., Katz J., Torner J., Wasko M.C., et al. Effects of postmenopausal hormone therapy on rheumatoid arthritis: the women's health initiative randomized controlled trials. Arthritis Rheum 2008, 59(3):302-310.
145. Bijlsma J.W., Huber-Bruning O., Thijssen J.H. Effect of oestrogen treatment on clinical and laboratory manifestations of rheumatoid arthritis. Ann Rheum Dis 1987, 46(10):777-779.
146. D'Elia H.F., Larsen A., Mattsson L.A., Waltbrand E., Kvist G., Mellstrom D., et al. Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. J Rheumatol 2003, 30(7):1456-1463.
147. Hall G.M., Daniels M., Huskisson E.C., Spector T.D. A randomised controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal rheumatoid arthritis. Ann Rheum Dis 1994, 53(2):112-116.
148. MacDonald A.G., Murphy E.A., Capell H.A., Bankowska U.Z., Ralston S.H. Effects of hormone replacement therapy in rheumatoid arthritis: a double blind placebo-controlled study. Ann Rheum Dis 1994, 53(1):54-57.
149. van den Brink H.R., van Everdingen A.A., van Wijk M.J., Jacobs J.W., Bijlsma J.W. Adjuvant oestrogen therapy does not improve disease activity in postmenopausal patients with rheumatoid arthritis. Ann Rheum Dis 1993, 52(12):862-865.
150. Straub R.H., Harle P., Atzeni F., Weidler C., Cutolo M., Sarzi-Puttini P. Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy. J Rheumatol 2005, 32(7):1253-1258.
151. Rovensky J., Kvetnansky R., Radikova Z., Imrich R., Greguska O., Vigas M., et al. Hormone concentrations in synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 2005, 23(3):292-296.
152. Schmidt M., Hartung R., Capellino S., Cutolo M., Pfeifer-Leeg A., Straub R.H. Estrone/17beta-estradiol conversion to, and tumor necrosis factor inhibition by, estrogen metabolites in synovial cells of patients with rheumatoid arthritis and patients with osteoarthritis. Arthritis Rheum 2009, 60(10):2913-2922.
153. Fairweather D., Frisancho-Kiss S., Rose N.R. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol 2008, 173(3):600-609.
154. van Vollenhoven R.F., Houbiers J.G., Buttgereit F., In 't Hout J., Boers M., Leij S., et al. The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine. Arthritis Rheum 2011, 62(2):351-358.
155. Roman-Blas J.A., Castaneda S., Cutolo M., Herrero-Beaumont G. Efficacy and safety of a selective estrogen receptor beta agonist, ERB-041, in patients with rheumatoid arthritis: a 12-week, randomized, placebo-controlled, phase II study. Arthritis Care Res (Hoboken) 2010, 62(11):1588-1593.
156. Cutolo M., Sulli A., Pizzorni C., Craviotto C., Prete C., Foppiani L., et al. Cortisol, dehydroepiandrosterone sulfate, and androstenedione levels in patients with polymyalgia rheumatica during twelve months of glucocorticoid therapy. Ann N Y Acad Sci 2002, 966:91-96.
157. Tengstrand B., Carlstrom K., Hafstrom I. Bioavailable testosterone in men with rheumatoid arthritis-high frequency of hypogonadism. Rheumatology (Oxford) 2002, 41(3):285-289.
158. Tengstrand B., Carlstrom K., Fellander-Tsai L., Hafstrom I. Abnormal levels of serum dehydroepiandrosterone, estrone, and estradiol in men with rheumatoid arthritis: high correlation between serum estradiol and current degree of inflammation. J Rheumatol 2003, 30(11):2338-2343.
159. Spector T.D., Ollier W.E., Perry L.A., Silman A.J. Evidence for similarity in testosterone levels in haplotype identical brothers. Dis Markers 1988, 6(2):119-125.
160. Masi A.T., Cutolo M. Perspectives on sex hormones and the systemic rheumatic diseases. Clin Exp Rheumatol 1995, 13(2):201-202.
161. Cutolo M., Balleari E., Giusti M., Intra E., Accardo S. Androgen replacement therapy in male patients with rheumatoid arthritis. Arthritis Rheum 1991, 34(1):1-5.
162. Ernestam S., Hafstrom I., Werner S., Carlstrom K., Tengstrand B. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function. J Rheumatol 2007, 34(7):1451-1458.
163. Booji A., Biewenga-Booji C.M., Huber-Bruning O., Cornelis C., Jacobs J.W., Bijlsma J.W. Androgens as adjuvant treatment in postmenopausal female patients with rheumatoid arthritis. Ann Rheum Dis 1996, 55(11):811-815.